The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
BIOHAVEN PHARMACTL HLDG CO L | COM | G11196105 | 131,744 | 1,111,111 | SH | DFND | 1 | 1,111,111 | 0 | 0 | |
VIRACTA THERAPEUTICS INC | COM | 92765F108 | 18 | 3,700 | SH | DFND | 1 | 3,700 | 0 | 0 | |
EPIZYME INC | COM | 29428V104 | 47,750 | 31,833,334 | SH | DFND | 1 | 9,166,667 | 0 | 0 | |
EPIZYME INC | COM | 29428V904 | 3,822 | 2,548,284 | SH | Call | DFND | 1 | 2,548,284 | 0 | 0 |
BIOCRYST PHARMACEUTICALS INC | COM | 09058V103 | 62,538 | 3,846,154 | SH | DFND | 1 | 3,846,154 | 0 | 0 |